Zealand: Deserves a closer look

BUY, Fair Value DKK125 vs. Under Review (+28%)
News published on April Monday 27, 2015
Share on

So far Zealand was seen as Sanofi’s partner for lixisenatide and considering the slow start of Lyxumia and delays in developing LixiLan it did not attract much attention. In addition, the rest of the pipeline was early-stage and was also lacking evidence of potential breakthrough innovation. But Zealand is changing and at least ongoing changes deserve a closer look as the downside appears limited whereas the upside can be huge.

For more information, plaese contact marketing@bryangarnier.com

The Essentials

Everything you need to know about investment banking dedicated to growth
Recent Transactions Highlights
From M&A, to IPOs see what’s been happening at Bryan, Garnier & Co this year
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities